NEW YORK, Sept. 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:US Cancer Vaccine Market Analysis 
Cancer vaccines are highly researched today owing to growing cancer incidences and an urgent need to control and prevent the massively penetrating disease. Amongst the highest incident cancers, prostate cancers are high in males and breast cancer in females. The introduction of Merck's Gardasil bought great attention to cancer vaccines. US represents the most promising market for cancer vaccines across the globe, accounting for around 49% share.
The prophylactic vaccines currently available in the market include Merck's Gardasil, GSK's Cervarix, and several other Hepatitis B vaccines while the only therapeutic vaccine in the market is Dendreon's Provenge. The report "US Cancer Vaccine Market Analysis", in such a scenario provides an analysis of the current market size for these vaccines along with future estimations. In-depth perspective has been provided for the various factors that will govern the growth of each of these vaccines along with the constraints that limit them.
Merck and GSK are expected to continue to be undefeated market leaders in the prophylactic cancer segment as the launch of a new cancer vaccine is unlikely in the next 3 years. The research and innovation for cancer vaccines is highly robust and several candidates are being studied for their role in cancer. Trials are focusing more on the therapeutic vaccines and this segment can be expected to evolve greatly in the years to come. Amongst the various studies, a vaccine for lung cancer